Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q2 2026 results on July 30, 2026. | Jul 16, 2026 |
| PTCT | PRESS-RELEASE | neutral | 1/10 | PTC Therapeutics, Inc. announced it will report its Q2 2026 results on July 30, 2026. | Jul 16, 2026 |
| GANX | 8-K | neutral | 4/10 | Gain Therapeutics filed an 8-K announcing that its cash and cash equivalents are expected to fund operations into Q2 202 | Jul 16, 2026 |
| ABUS | 8-K | bullish | 7/10 | Arbutus received ~$178M from the Moderna settlement, filed three international patent lawsuits against Pfizer/BioNTech, | Jul 16, 2026 |
| GRFS | PRESS-RELEASE | neutral | 4/10 | Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immu | Jul 16, 2026 |
| SNTI | S-3/A | bearish | 7/10 | Senti Biosciences filed Amendment No. 1 to its S-3 shelf registration statement to register 15,971,890 shares of common | Jul 16, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber announced $2.09M in purchase orders at its subsidiary Quantum Drones Corporation, received as part of the | Jul 16, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell announced that Sunnybrook's Odette Cancer Centre has joined its pivotal Phase 3 study of Bria-IMT plus an immun | Jul 16, 2026 |
| MDCX | PRESS-RELEASE | bullish | 5/10 | Medicus Pharma received FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in men with a | Jul 16, 2026 |
| ATAI | DEFA14A, 8-K | bullish | 7/10 | Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $6.75 per share in cash plus up to $2.50 per share in conti | Jul 16, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron reported FY26 global sales of AUD$7.7M, up 6% year-over-year, driven by 10% growth in Australia and 7% in the US | Jul 16, 2026 |
| SIGY | 15-12G | bearish | 7/10 | Sigyn Therapeutics filed a Form 15-12G to terminate its SEC registration under Section 12(g) and suspend its duty to fil | Jul 16, 2026 |
| ISCO | 8-K | bullish | 6/10 | International Stem Cell Corporation (ISCO) signed a definitive agreement to sell its wholly-owned subsidiary, Lifeline C | Jul 16, 2026 |
| ZYME | PRESS-RELEASE | neutral | 1/10 | Zymeworks Inc. announced it will report its Q2 2026 results on August 6, 2026. | Jul 16, 2026 |
| SLGL | INSIDER-BUY | bullish | 4/10 | Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, purchased 1,304 shares for a total of $96K in open-market | Jul 16, 2026 |
| ARGX | PRESS-RELEASE | neutral | 1/10 | argenx SE announced it will report its Q2 2026 results on July 23, 2026. | Jul 16, 2026 |
| MOLN | PRESS-RELEASE | neutral | 4/10 | Molecular Partners announced dosing of first patients in a Phase 2 proof-of-concept study (TACTIC) of MP0317 combined wi | Jul 16, 2026 |
| MLYS | CLUSTER | neutral | 3/10 | CEO Jon Congleton and CMO David Malcom Rodman sold a combined $679K of MLYS stock in open-market sales on July 13, 2026, | Jul 15, 2026 |
| FULC | 3 | bullish | 6/10 | Kevin Tang and Tang Capital Management LLC filed a Form 3 initial statement of beneficial ownership, disclosing a 6,663, | Jul 15, 2026 |
| MPLT | 144 | neutral | 2/10 | Officer Jonathan Gillis filed a Form 144 to sell 36,979 shares (~$1.4M) of MapLight Therapeutics common stock solely to | Jul 15, 2026 |
| ORKA | CLUSTER | neutral | 2/10 | Two insiders (CMO and SVP Finance) sold shares totaling ~$1.45M, but this represents only 0.027% of the $5.3B market cap | Jul 15, 2026 |
| ANIP | COURT-RULING | bearish | 6/10 | The Delaware Superior Court denied ANI Pharmaceuticals' motion for a new trial and judgment as a matter of law, upholdin | Jul 15, 2026 |
| CGON | COURT-RULING | bullish | 7/10 | The Delaware Superior Court denied ANI Pharmaceuticals' post-trial motion for a new trial and judgment as a matter of la | Jul 15, 2026 |
| AEON | 8-K | bearish | 8/10 | AEON Biopharma is conducting a massively dilutive public offering, selling 17.85M shares, 24.84M pre-funded warrants, an | Jul 15, 2026 |
| SPRC | 6-K | neutral | 4/10 | SciSparc's subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, | Jul 15, 2026 |
| MPLT | 144 | neutral | 2/10 | Officer Lillie James Woodruff filed a Form 144 to sell 18,835 shares of MapLight Therapeutics common stock, with an appr | Jul 15, 2026 |
| ASND | 6-K | neutral | 2/10 | Ascendis Pharma filed a 6-K reporting the grant of 14,060 warrants to employees at an exercise price of $265.57 per shar | Jul 15, 2026 |
| RLYB | S-4 | neutral | 6/10 | Rallybio Corp (RLYB) filed an S-4 registration statement for a proposed reverse merger with private biotech Avenzo Thera | Jul 15, 2026 |
| CNTN | 3 | neutral | 2/10 | Pamela L. Carter filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero shares of Canton | Jul 15, 2026 |
| LLY | COURT-RULING | neutral | 2/10 | A magistrate judge in the Northern District of California granted in part and denied in part a discovery motion in Eli L | Jul 15, 2026 |